This survey aims to determine the following information and the need for conducting specified drug use-results surveys and post-marketing clinical studies in patients using Betanis (generic name: mirabegron):~The occurrence of adverse drug reactions in clinical settings.~Factors potentially impacting safety, effectiveness, and other aspects.~Items of Particular Interest:~Safety and effectiveness in patients with hepatic impairment and patients with renal impairment.~Safety and effectiveness when mirabegron is used concomitantly with other drugs (α1 blockers, anticholinergic agents, 5α reductase inhibitors, drugs with a potent CYP3A4-inhibiting effect, drugs with a CYP3A4-inducing effect, drugs metabolized primarily by CYP2D6, and other frequently used drugs).~The occurrence of cardiovascular adverse events.~The occurrence of adverse events related to increased intraocular pressure.~The occurrence of urinary retention
This study is to determine the following information.~The occurrence of adverse drug reactions in clinical settings.~Factors potentially impacting safety, effectiveness, and other aspects.